Nkarta, Inc. (NKTX)
NKTX Stock Price Chart
Explore Nkarta, Inc. interactive price chart. Choose custom timeframes to analyze NKTX price movements and trends.
NKTX Company Profile
Discover essential business fundamentals and corporate details for Nkarta, Inc. (NKTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jul 2020
Employees
157.00
Website
https://www.nkartatx.comCEO
Paul J. Hastings
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Financial Timeline
Browse a chronological timeline of Nkarta, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.32.
Earnings released on 12 Aug 2025
EPS came in at -$0.31 surpassing the estimated -$0.37 by +16.22%.
Earnings released on 14 May 2025
EPS came in at -$0.43 surpassing the estimated -$0.44 by +2.27%.
Earnings released on 26 Mar 2025
EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.63%.
Earnings released on 7 Nov 2024
EPS came in at -$0.39 falling short of the estimated -$0.37 by -5.41%.
Earnings released on 13 Aug 2024
EPS came in at -$0.34 surpassing the estimated -$0.49 by +30.61%.
Earnings released on 9 May 2024
EPS came in at -$0.58 falling short of the estimated -$0.56 by -3.57%.
Earnings released on 21 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$0.62 by +8.06%, while revenue for the quarter reached $10.54M .
Earnings released on 9 Nov 2023
EPS came in at -$0.52 surpassing the estimated -$0.67 by +22.39%.
Earnings released on 10 Aug 2023
EPS came in at -$0.68 surpassing the estimated -$0.69 by +1.45%.
Earnings released on 11 May 2023
EPS came in at -$0.63 surpassing the estimated -$0.71 by +11.27%.
Earnings released on 16 Mar 2023
EPS came in at -$0.67 falling short of the estimated -$0.65 by -3.08%.
Earnings released on 9 Nov 2022
EPS came in at -$0.58 surpassing the estimated -$0.62 by +6.45%.
Earnings released on 11 Aug 2022
EPS came in at -$0.48 surpassing the estimated -$0.59 by +18.64%.
Earnings released on 12 May 2022
EPS came in at -$0.63 surpassing the estimated -$0.73 by +13.70%.
Earnings released on 17 Mar 2022
EPS came in at -$0.69 surpassing the estimated -$0.75 by +8.00%.
Earnings released on 10 Nov 2021
EPS came in at -$0.68 surpassing the estimated -$0.71 by +4.23%.
Earnings released on 12 Aug 2021
EPS came in at -$0.66 falling short of the estimated -$0.65 by -1.54%.
Earnings released on 13 May 2021
EPS came in at -$0.59 falling short of the estimated -$0.53 by -11.32%.
Earnings released on 25 Mar 2021
EPS came in at -$0.55 falling short of the estimated -$0.45 by -22.22%.
Earnings released on 12 Nov 2020
EPS came in at -$0.44 falling short of the estimated -$0.39 by -12.82%.
NKTX Stock Performance
Access detailed NKTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.